This content was originally shared by a registered user, but access has expired. Create a free account to gain permanent access to all PracticeUpdate content.
Already Have An Account? Log in Now
Individualized Axitinib Regimen for Patients With Metastatic Renal Cell Carcinoma After Treatment With Checkpoint Inhibitors
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
Individualised Axitinib Regimen for Patients With Metastatic Renal Cell Carcinoma After Treatment With Checkpoint Inhibitors: A Multicentre, Single-Arm, Phase 2 Study
Lancet Oncol 2019 Aug 16;[EPub Ahead of Print], MC Ornstein, SK Pal, LS Wood, JM Tomer, BP Hobbs, XS Jia, KD Allman, A Martin, T Olencki, NB Davis, TD Gilligan, A Mortazavi, WK Rathmell, JA Garcia, BI RiniFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.